ES2981472T3 - Procedimientos para el tratamiento de infecciones bacterianas utilizando oritavancina - Google Patents

Procedimientos para el tratamiento de infecciones bacterianas utilizando oritavancina Download PDF

Info

Publication number
ES2981472T3
ES2981472T3 ES10772493T ES10772493T ES2981472T3 ES 2981472 T3 ES2981472 T3 ES 2981472T3 ES 10772493 T ES10772493 T ES 10772493T ES 10772493 T ES10772493 T ES 10772493T ES 2981472 T3 ES2981472 T3 ES 2981472T3
Authority
ES
Spain
Prior art keywords
glycopeptide antibiotic
fraction
bound
serum proteins
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10772493T
Other languages
English (en)
Spanish (es)
Inventor
Geoffrey Mckay
Sylvain Beaulieu
Dario Lehoux
Thomas Parr
Gregory Moeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melinta Therapeutics LLC
Original Assignee
Melinta Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melinta Therapeutics LLC filed Critical Melinta Therapeutics LLC
Application granted granted Critical
Publication of ES2981472T3 publication Critical patent/ES2981472T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES10772493T 2009-04-28 2010-04-26 Procedimientos para el tratamiento de infecciones bacterianas utilizando oritavancina Active ES2981472T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17345109P 2009-04-28 2009-04-28
PCT/US2010/032441 WO2010129233A2 (en) 2009-04-28 2010-04-26 Methods of treating bacterial infections using oritavancin

Publications (1)

Publication Number Publication Date
ES2981472T3 true ES2981472T3 (es) 2024-10-09

Family

ID=43050709

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10772493T Active ES2981472T3 (es) 2009-04-28 2010-04-26 Procedimientos para el tratamiento de infecciones bacterianas utilizando oritavancina

Country Status (11)

Country Link
US (1) US9682061B2 (enExample)
EP (1) EP2424559B1 (enExample)
JP (1) JP2012525391A (enExample)
CN (1) CN102573882A (enExample)
AU (1) AU2010245097B2 (enExample)
BR (1) BRPI1014767A2 (enExample)
CA (1) CA2760159C (enExample)
ES (1) ES2981472T3 (enExample)
PL (1) PL2424559T3 (enExample)
PT (1) PT2424559T (enExample)
WO (1) WO2010129233A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5782615B2 (ja) * 2008-08-30 2015-09-24 ザ メディシンズ カンパニー オリタバンシンの単回用量を用いる治療の方法
WO2012011450A1 (ja) * 2010-07-20 2012-01-26 シャープ株式会社 コンテンツ配信装置、コンテンツ再生装置、コンテンツ配信システム、コンテンツ配信装置の制御方法、制御プログラム、および、記録媒体
MX385925B (es) 2014-07-17 2025-03-18 The Medicines Co Oritavancina de alta pureza y método para producir la misma.
US10534895B2 (en) 2015-01-20 2020-01-14 Icpd Technologies, Llc System and method for ranking options for medical treatments
CA3014294A1 (en) * 2016-02-18 2017-08-24 Melinta Therapeutics, Inc. Oritavancin formulations
GB2577420B (en) * 2017-05-22 2022-07-06 Insmed Inc Glycopeptide derivative compounds and uses thereof
KR102189125B1 (ko) * 2018-11-30 2020-12-10 주식회사 리얼타임테크 로그 수집 시스템 및 그 수집 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750509A (en) 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
DE60136926D1 (de) 2000-05-02 2009-01-22 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
US20030176327A1 (en) * 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
CA2664444C (en) * 2006-09-25 2015-10-27 Melinta Therapeutics, Inc. Use of oritavancin for prevention and treatment of anthrax
WO2008118784A1 (en) 2007-03-23 2008-10-02 Targanta Therapeutics Corp. Glycopeptide and lipoglycopeptide antibiotics with improved solubility
US8518873B2 (en) 2007-09-12 2013-08-27 The Medicines Company Method of inhibiting clostridium difficile by administration of oritavancin
JP5782615B2 (ja) * 2008-08-30 2015-09-24 ザ メディシンズ カンパニー オリタバンシンの単回用量を用いる治療の方法

Also Published As

Publication number Publication date
CA2760159A1 (en) 2010-11-11
WO2010129233A9 (en) 2011-02-03
PL2424559T3 (pl) 2024-07-29
US20120035097A1 (en) 2012-02-09
CA2760159C (en) 2021-01-12
WO2010129233A2 (en) 2010-11-11
EP2424559A1 (en) 2012-03-07
AU2010245097A9 (en) 2015-08-13
JP2012525391A (ja) 2012-10-22
EP2424559A4 (en) 2012-10-03
CN102573882A (zh) 2012-07-11
AU2010245097B2 (en) 2015-08-13
BRPI1014767A2 (pt) 2016-04-19
US9682061B2 (en) 2017-06-20
AU2010245097A1 (en) 2011-11-10
EP2424559B1 (en) 2024-04-03
PT2424559T (pt) 2024-04-30

Similar Documents

Publication Publication Date Title
ES2994966T3 (en) Single doses of oritavancin for treating or preventing a bacterial infection
CA2760159C (en) Methods of treating bacterial infections using oritavancin
US20240009113A1 (en) Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
CA2664444C (en) Use of oritavancin for prevention and treatment of anthrax
US20150148286A1 (en) Potentiation of antibiotic treatment with a protein-lipid complex
US9775878B2 (en) Methods for treating bacterial infections using oritavancin and polymyxins
US20250099536A1 (en) Pristinamycin ia and flopristin combinations in treating or preventing bacterial infections
ES2949169T3 (es) Procedimientos para tratar la bacteriemia y la osteomielitis utilizando oritavancina
AU2013202360B2 (en) Methods of treatment using single doses of oritavancin
US20210393735A1 (en) Pharmaceutical composition comprising teicoplanin